Evidence map›Paper›PMID 36387653›Full record

ArticleJournal of family medicine and primary care2022

Miller Fisher syndrome associated with COVID 19.

Arjimand Yaqoob, Waseem Dar, Zubair Khuja, Immia Bukhari, Adnan Raina, Hilal Ganie, Amit Chandra, Maqbool Wani, Ravouf Asimi, Faizan Wani

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Arjimand YaqoobDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Waseem DarDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Zubair KhujaDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Immia BukhariDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Adnan RainaDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Hilal GanieDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Amit ChandraDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Maqbool WaniDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Ravouf AsimiDepartment of Neurology, SKIMS, Jammu and Kashmir, India.
Faizan WaniDepartment of General Medicine, SKIMS, Jammu and Kashmir, India.
Sher-i-Kashmir Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Miller Fisher syndrome (MFS), is an acute peripheral neuropathy, a variant of Guillain-Barre syndrome, that develops following exposure to different viral, bacterial, and fungal pathogens. Patients usually present with a triad of ophthalmoplegia, ataxia, and areflexia. During Covid pandemic MFS has been described associated with novel coronavirus disease 2019 (COVID-19). Here we describe the clinical course, Cerebrospinal fluid (CSF) findings, nerve conduction studies, treatment and outcome of the patient having MFS concurrent with COVID 19.

Indexed as

COVID-19GBSMFSSARS-CoV-2

Identifiers

PMID36387653
PMCPMC9648327
OpenAlexW4289209695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.